Republic of Korea
Tuberculosis profile
Population  2013 49 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.6 (2.4–2.7) 5.2 (4.9–5.5)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.01 (0–0.02)
Prevalence  (includes HIV+TB) 71 (58–85) 143 (117–172)
Incidence  (includes HIV+TB) 48 (45–52) 97 (92–105)
Incidence (HIV+TB only) 0.047 (0.045–0.099) 0.1 (0.09–0.2)
Case detection, all forms (%) 87 (80–92)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 2.7 (2.1–3.4) 14 (10–19)
MDR-TB cases among notified pulmonary
TB cases
780 (600–980) 1 200 (850–1 600)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 18 860   2 957
Pulmonary, clinically diagnosed 9 860   1 699
Extrapulmonary 7 369   834
       
Total new and relapse 41 579    
Previously treated, excluding relapses 3 713    
Total cases notified 45 292    
Among 41 579 new and relapse cases:
226 (<1%) cases aged under 15 years; male:female ratio: 1.4
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 13 190 (70%) 3 953 (43%) 17 143
Laboratory-confirmed RR-/MDR-TB cases     1 097
Patients started on MDR-TB treatment     951
TB/HIV 2013 Number (%)
TB patients with known HIV status    
HIV-positive TB patients    
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 81
Previously treated cases, excluding relapse, registered in 2012 76
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 59
XDR-TB cases started on second-line treatment in 2011 45
Laboratories 2013  
Smear (per 100 000 population) 1.2
Culture (per 5 million population) 10.1
Drug susceptibility testing (per 5 million population) 1.2
Sites performing Xpert MTB/RIF 45
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 37
% Funded domestically 100%
% Funded internationally 0%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-04-26 Data: www.who.int/tb/data